{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SGN-30&page=2", "query": { "intervention": "SGN-30", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SGN-30&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-27T21:16:29.720Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01712490", "title": "A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hodgkin Lymphoma" ], "interventions": [ { "name": "brentuximab vedotin", "type": "DRUG" }, { "name": "doxorubicin", "type": "DRUG" }, { "name": "bleomycin", "type": "DRUG" }, { "name": "vinblastine", "type": "DRUG" }, { "name": "dacarbazine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1334, "start_date": "2012-11-09", "completion_date": "2026-02-02", "has_results": true, "last_update_posted_date": "2026-02-27", "last_synced_at": "2026-09-27T21:16:29.720Z", "location_count": 83, "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Tucson, Arizona + 80 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Burbank", "state": "California" }, { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01712490" }, { "nct_id": "NCT03712202", "title": "Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ann Arbor Stage I Hodgkin Lymphoma", "Ann Arbor Stage I Mixed Cellularity Classic Hodgkin Lymphoma", "Ann Arbor Stage I Nodular Sclerosis Classic Hodgkin Lymphoma", "Ann Arbor Stage IA Hodgkin Lymphoma", "Ann Arbor Stage IB Hodgkin Lymphoma", "Ann Arbor Stage II Hodgkin Lymphoma", "Ann Arbor Stage IIA Hodgkin Lymphoma", "Ann Arbor Stage IIB Hodgkin Lymphoma", "Classic Hodgkin Lymphoma", "Lymphocyte-Rich Classic Hodgkin Lymphoma", "Ann Arbor Stage I Lymphocyte-Depleted Classic HL", "Ann Arbor Stage II Lymphocyte-Depleted Classic HL", "Ann Arbor Stage II Mixed Cellularity Classic HL", "Ann Arbor Stage II Nodular Sclerosis Classic HL" ], "interventions": [ { "name": "Bleomycin", "type": "DRUG" }, { "name": "Brentuximab Vedotin", "type": "DRUG" }, { "name": "Dacarbazine", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Vinblastine", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 155, "start_date": "2018-11-28", "completion_date": "2024-12-23", "has_results": false, "last_update_posted_date": "2024-11-06", "last_synced_at": "2026-09-27T21:16:29.720Z", "location_count": 17, "location_summary": "Birmingham, Alabama • Duarte, California • San Diego, California + 12 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03712202" }, { "nct_id": "NCT05404945", "title": "Fitness-adapted, Pembrolizumab-based Therapy for Untreated Classical Hodgkin Lymphoma Patients 60 Years of Age and Above", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Classical Hodgkin Lymphoma" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Vinblastine", "type": "DRUG" }, { "name": "Dacarbazine", "type": "DRUG" }, { "name": "Brentuximab vedotin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Virginia", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "ALL", "summary": "60 Years and older" }, "enrollment_count": 24, "start_date": "2022-07-26", "completion_date": "2027-10-03", "has_results": false, "last_update_posted_date": "2026-05-14", "last_synced_at": "2026-09-27T21:16:29.720Z", "location_count": 3, "location_summary": "New Brunswick, New Jersey • Philadelphia, Pennsylvania • Charlottesville, Virginia", "locations": [ { "city": "New Brunswick", "state": "New Jersey" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Charlottesville", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05404945" }, { "nct_id": "NCT02254239", "title": "Everolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Hodgkin Lymphoma", "Refractory Hodgkin Lymphoma" ], "interventions": [ { "name": "Brentuximab Vedotin", "type": "DRUG" }, { "name": "Everolimus", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2016-02-04", "completion_date": "2018-12-12", "has_results": false, "last_update_posted_date": "2019-12-12", "last_synced_at": "2026-09-27T21:16:29.720Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02254239" }, { "nct_id": "NCT02096042", "title": "Phase I/II - Brentuximab/5-Azacytidine in Acute Myeloid Leukemia (AML)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "Brentuximab Vedotin", "type": "DRUG" }, { "name": "5-Azacytidine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2014-04", "completion_date": "2016-08", "has_results": true, "last_update_posted_date": "2023-10-10", "last_synced_at": "2026-09-27T21:16:29.720Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02096042" }, { "nct_id": "NCT01657331", "title": "Brentuximab Vedotin and Bendamustine for the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (ALCL)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Hodgkin Lymphoma", "Anaplastic Large Cell Lymphoma" ], "interventions": [ { "name": "Brentuximab Vedotin", "type": "DRUG" }, { "name": "Bendamustine", "type": "DRUG" }, { "name": "Neulasta", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Columbia University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 65, "start_date": "2012-07", "completion_date": "2018-06", "has_results": true, "last_update_posted_date": "2026-06-24", "last_synced_at": "2026-09-27T21:16:29.720Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01657331" }, { "nct_id": "NCT02689219", "title": "Brentuximab Vedotin in Relapsed/Refractory Germ Cell Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Germ Cell Tumors", "Testis Cancer", "Testicular Cancer", "Embryonal Carcinoma", "Nonseminomatous Germ Cell Tumor" ], "interventions": [ { "name": "Brentuximab Vedotin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nabil Adra", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2016-03-09", "completion_date": "2019-01-23", "has_results": true, "last_update_posted_date": "2019-12-10", "last_synced_at": "2026-09-27T21:16:29.720Z", "location_count": 4, "location_summary": "Los Angeles, California • Indianapolis, Indiana • New York, New York", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02689219" }, { "nct_id": "NCT02164006", "title": "Novel PI3K Delta Inhibitor TGR-1202, in Combination With Brentuximab Vedotin for Hodgkin's Lymphoma Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hodgkin's Lymphoma" ], "interventions": [ { "name": "TGR-1202 + brentuximab vedotin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "TG Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2014-06-11", "completion_date": "2016-05", "has_results": false, "last_update_posted_date": "2019-10-02", "last_synced_at": "2026-09-27T21:16:29.720Z", "location_count": 4, "location_summary": "Duarte, California • San Diego, California • Sarasota, Florida + 1 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT02164006" }, { "nct_id": "NCT01393717", "title": "Brentuximab Vedotin Before Autologous Stem Cell Transplant in Treating Patients With Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Hodgkin Lymphoma", "Refractory Hodgkin Lymphoma" ], "interventions": [ { "name": "brentuximab vedotin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "11 Years", "maximum_age": null, "sex": "ALL", "summary": "11 Years and older" }, "enrollment_count": 57, "start_date": "2011-10-20", "completion_date": "2017-02-01", "has_results": true, "last_update_posted_date": "2018-04-26", "last_synced_at": "2026-09-27T21:16:29.720Z", "location_count": 2, "location_summary": "Duarte, California • New York, New York", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01393717" }, { "nct_id": "NCT01616680", "title": "Brentuximab Vedotin in Treating Patients With Steroid-Resistant Acute Graft-Versus-Host Disease", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Graft Versus Host Disease" ], "interventions": [ { "name": "brentuximab vedotin", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 0, "start_date": "2012-09", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-06-27", "last_synced_at": "2026-09-27T21:16:29.720Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01616680" } ] }